Nebenwirkungen · Vegzelma
Vegzelma 25 mg/mL concentrate for solution for infusion. · Abschnitt 4.8 · PDF-Seite 17
HOS-295398 · Präparat HOS-288208
In patients with NSCLC excluding predominant squamous histology, all Grade reactions were seen with a frequency of up to 9.3% when treated with bevacizumab plus chemotherapy compared with up to 5% in the patients treated with chemotherapy alone. Grade 3-5 reactions have been observed in up to 2.3% of patients treated with bevacizumab plus chemotherapy as compared with < 1% with chemotherapy alone (NCI-CTCAE v.3). Major or massive pulmonary haemorrhage/haemoptysis can occur suddenly and up to two thirds of the serious pulmonary haemorrhages resulted in a fatal outcome.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-28T13:36:00Z · SHA-256 20ea68c53f599641b5af70f18c5c64bf44459b6d38ae88a3bfe72b01d8f54018 · Passage 5a684089ff1526badb6d5e00b68bb6e608b36d9f84fbda9f319a8cfcd8b73be9 · Zeichen 28013–28587 im Abschnitt